"Cytochrome P-450 CYP2C8" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A liver microsomal cytochrome P450 hydroxylase that oxidizes a broad spectrum of substrates including STEROIDS, FATTY ACIDS, and XENOBIOTICS. Examples of pharmaceutical substrates for CYP2C8 include; PACLITAXOL; torsemide; and; AMODIAQUINE
| Descriptor ID |
D065727
|
| MeSH Number(s) |
D08.244.453.005.590 D08.244.453.491.368 D08.811.682.690.708.170.010.590 D08.811.682.690.708.170.450.360 D12.776.422.220.453.010.590 D12.776.422.220.453.491.360
|
| Concept/Terms |
Cytochrome P-450 CYP2C8- Cytochrome P-450 CYP2C8
- CYP2C8, Cytochrome P-450
- Cytochrome P 450 CYP2C8
- P-450 CYP2C8, Cytochrome
- Cytochrome P450 MP-20
- Cytochrome P450 MP 20
- P450 MP-20, Cytochrome
- Cytochrome P450, Family 2, Subfamily C, Polypeptide 8
- S-Mephenytoin 4-Hydroxylase
- 4-Hydroxylase, S-Mephenytoin
- S Mephenytoin 4 Hydroxylase
- CYP2C8
- CYPIIC8
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2C8".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2C8".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2C8" by people in this website by year, and whether "Cytochrome P-450 CYP2C8" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2C8" by people in Profiles.
-
CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project. J Mol Diagn. 2022 04; 24(4):337-350.
-
Quantitation of paclitaxel, and its 6-alpha-OH and 3-para-OH metabolites in human plasma by LC-MS/MS. J Pharm Biomed Anal. 2019 Aug 05; 172:26-32.
-
Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May; 42(5):863-6.
-
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. Cancer Chemother Pharmacol. 2013 Jan; 71(1):193-202.
-
Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May; 38(5):871-8.